Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 8/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 6/20 | 0.41 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 3/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375492 | 0.90 | SLC6A9 (0.51) | SLC6A9SLC6A5KCNH2ROCK2CYP2D6 | |
| SCHEMBL375772 | 0.88 | P2RX3 (0.42) | SLC6A9SLC6A5KCNH2ROCK2SLC2A1 | |
| SCHEMBL375006 | 0.87 | PDE4D (0.39) | SLC6A9SLC6A5KCNH2 | |
| SCHEMBL375095 | 0.85 | TACR1 (0.43) | SLC6A9SLC6A5KCNH2TACR1 | |
| SCHEMBL375083 | 0.84 | TACR1 (0.46) | SLC6A9SLC6A5KCNH2ROCK2SLC2A1 | |
| SCHEMBL1395302 | 0.84 | TACR1 (0.37) | SLC6A9SLC6A5KCNH2ROCK2SLC2A1 | |
| SCHEMBL375145 | 0.82 | SLC6A4 (0.49) | KCNH2CYP2D6CYP3A4 | |
| SCHEMBL374835 | 0.82 | SLC6A2 (0.40) | MEP1BKCNH2TACR1 | |
| SCHEMBL375116 | 0.81 | KDM4E (0.40) | SLC6A9SLC6A5KCNH2CYP2D6CYP3A4 | |
| SCHEMBL375594 | 0.80 | KCNH2 (0.39) | SLC6A9SLC6A5KCNH2ROCK2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623898-B2 | Glycine transporter inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| EP-2409976-A1 | GLYCINE TRANSPORTER INHIBITOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | SLC18A2, SLC1A2, SLC6A1 | SLC6A9 8/4885SLC6A5 4/4885MEP1B 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.